Breast cancer treatment depends upon molecular subtypes which are generally characterized on the basis of the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), breast cancer which is negative in ER, PR, and HER2 is termed as triple-negative breast cancer (TNBC) (43). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.